Please ensure Javascript is enabled for purposes of website accessibility

Biotech Winners: Pernix, Myriad, Repros, OraSure

By Dave Williamson and Max Macaluso - Feb 6, 2014 at 8:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pernix, Myriad, Repros and OraSure were four big winners in the biotech space during the past two days. Here's the back story on these pharmaceutical stock pops.

In this video from Thursday's Market Checkup, Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today.

In this segment, a look at some big winners during the past two days in the biotech space. Pernix (NYSEMKT: PTX) saw a nearly 70% pop upward yesterday as the company settled a few housekeeping items, including hiring a new CEO, settling a pending legal matter, and securing $65 million in funding, a lifesaver compared to its cash-on-hand situation prior to this. Myriad Genetics (MYGN 2.00%), maker of a test for breast cancer, is up 15% after its fiscal second-quarter net income soared by 43.7%, to $50.4 million, with sales increasing $55 million, to $204.1 million. Repros Therapeutics (NASDAQ: RPRX) is up 15% after positive meetings with the FDA over Androxal, its testosterone replacement drug. The company now believes it will not have to run any additional safety studies, and will be able to file for approval this year, which had investors cheering. And OraSure (OSUR 0.55%) is up 10% after reporting strong earnings, with revenue coming in at $28.8 million, which was a 30% improvement and a solid beat.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OraSure Technologies, Inc. Stock Quote
OraSure Technologies, Inc.
OSUR
$5.48 (0.55%) $0.03
Myriad Genetics, Inc. Stock Quote
Myriad Genetics, Inc.
MYGN
$21.97 (2.00%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.